Gujarat Themis Biosyn reported a 22% year-on-year increase in standalone net profit to ₹110.67 lakh for the quarter ended June 30, 2026, driven by a 22% rise in income from operations to ₹437.90 lakh. The Board of Directors approved the unaudited standalone and consolidated financial results on August 7, 2026, following a review by the Audit Committee and a limited review by statutory auditors GMJ & Co.

The company’s total income stood at ₹439.22 lakh, compared to ₹361.47 lakh in the corresponding quarter of the previous year. Total expenses decreased to ₹287.56 lakh from ₹240.28 lakh in the prior year period but fell 7% quarter-on-quarter from ₹308.18 lakh. Profit before tax was ₹151.65 lakh, up from ₹121.20 lakh in Q1FY26. Tax expenses amounted to ₹40.99 lakh, comprising current tax of ₹27.17 lakh and deferred tax of ₹13.82 lakh.

Key Financial Metrics

The consolidated financial results mirrored the standalone figures, as the newly incorporated subsidiaries—Themis Biosyn Japan Limited and Themis Biosyn Ireland Private Limited—had not commenced operations and recorded nil revenue or profit. Consequently, there was no impact on the consolidated net profit or comprehensive income. The comparative consolidated figures for previous periods remain identical to the standalone figures as no subsidiaries existed during those periods.

What the Numbers Show

A notable divergence in the cost structure is visible in finance costs, which surged to ₹17.87 lakh in Q1FY27 from just ₹0.42 lakh in the corresponding quarter of FY26. This sharp increase suggests a potential shift in debt utilization or interest-bearing liabilities, even as overall revenue growth remained robust. Meanwhile, employee benefit expenses rose 52% year-on-year to ₹47.21 lakh, indicating increased operational staffing or compensation costs amidst the revenue expansion. The company operates in a single business segment manufacturing fermentation-based pharmaceutical intermediates and APIs, with no reportable segments under Ind AS-108.

Sachin D. Patel has acquired 5,23,560 equity shares of Gujarat Themis Biosyn Limited from Pharmaceutical Business Group India Limited in an inter-se transfer within the promoter group. The transaction, completed on July 30, 2026, was executed at a price of ₹382 per share. This acquisition increases Patel’s stake in the company from 2.29% to 2.77% of the total diluted share capital, while the seller’s holding decreases from 47.02% to 46.54%. The move reflects internal restructuring among key stakeholders without altering the overall promoter group control.

The disclosure was submitted to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 4, 2026, under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. A prior intimation regarding this inter-se transfer was filed with the exchanges on July 14, 2026, complying with the requirement under Regulation 10(5) to disclose such transactions four working days prior to execution. The exemption from making an open offer was claimed under Regulation 10(1)(a)(ii), which applies to transfers between persons named as promoters in the shareholding pattern.

Transaction Details

Shareholding Structure

The table below outlines the change in shareholding for both the acquirer and the transferor following the transaction:

What the Numbers Show

The transaction represents a consolidation of holdings within the promoter circle rather than an entry by new external capital. With the transferor, Pharmaceutical Business Group India Limited, retaining a substantial 46.54% stake, the overall promoter group influence remains stable. The specific price of ₹382 per share serves as a reference point for recent valuation benchmarks within the promoter group, though it does not reflect open market trading dynamics. Such inter-se transfers are common for estate planning or internal realignment of equity among founding families and associated entities.